PuraPharm Updates Board Composition and Committee Roles

PuraPharm Corp. Ltd. ( (HK:1498) ) has provided an announcement.

PuraPharm Corporation Limited has released an updated list of its board of directors and clarified their respective roles and functions across key governance committees. The company detailed the composition of executive, non-executive and independent non-executive directors, as well as their memberships and chairmanships of the audit, remuneration and nomination committees, signaling a continued emphasis on board oversight and corporate governance structure.

The board is chaired by executive director Mr. Chan Yu Ling, Abraham, while independent non-executive directors, including Dr. Hung Ting On, John and Dr. Leung Lim Kin, Simon, assume leadership positions on the board committees. This delineation of responsibilities highlights the firm’s reliance on independent oversight in areas such as auditing, pay and board appointments, which may support regulatory compliance and bolster investor confidence in the company’s governance framework.

More about PuraPharm Corp. Ltd.

PuraPharm Corporation Limited is a Hong Kong-listed company engaged in the traditional Chinese medicine and healthcare sector. The group focuses on developing, manufacturing and selling Chinese herbal products and related remedies, targeting both local and international markets through retail and professional channels.

Average Trading Volume: 227,865

Technical Sentiment Signal: Sell

Current Market Cap: HK$157.8M

For detailed information about 1498 stock, go to TipRanks’ Stock Analysis page.